Advanced search
Start date
Betweenand

Processing and validation of umbilical cord blood components for transfusion medicine

Grant number: 16/25281-0
Support type:Regular Research Grants
Duration: March 01, 2018 - February 29, 2020
Field of knowledge:Health Sciences - Medicine
Principal Investigator:Elenice Deffune
Grantee:Elenice Deffune
Home Institution: Faculdade de Medicina (FMB). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil
Assoc. researchers:Ângela Cristina Malheiros Luzo
Associated scholarship(s):18/04787-9 - Processing and validation of blood components obtained from umbilical and placentary cord blood for use in transfusion medicine, BP.TT

Abstract

Transfusion therapy in neonatology is a consistent practice in intensive care units, especially in extremely low birth weight infants (ELBW). However, studies point to clinical implications caused by the exposure of these patients to transfusion, which may interfere with their development late. Alternatives to reduce the need for transfusion in the neonatal period for ELBW are described, among them the late clamping of the umbilical cord, which causes a greater return of placental blood to the new-born, thus reducing the need for transfusion. However, for ELBW, length of hospital stay may extend, and even with the use of this technique, the patient may require blood transfusion. Umbilical cord blood (UCB) has been explored over the years by hemotherapy, cell therapy and regenerative medicine because it is a material rich in cells and protein components. In view of this, the present work was outlined with the proposal to explore the quality of this material, in the form of blood components, mainly concentrated red blood cells, to enable its use in ELBW transfusion. The project in partnership with UNICAMP Cord Blood Bank aims to validate the processing and to evaluate the quality of the blood components obtained from UCB in comparison with adult blood transfusions, which are currently used by the transfusion services, in order to clarify which would be the advantages of using this material for ELBW transfusion. Thus, the surplus pockets of the UCB production process that present low cellularity (<8x108 of total nucleated cells) for processing to obtain hematopoietic stem cells will be used to carry out the project. The processing will be performed by conventional method, the same used by the Blood Banks for preparation of the blood components, through centrifugation and automated separation; and also using the same equipment that performs the UCB processing in the Cord Blood Banks, the SEPAX 2" from Biosafe". Therefore, it is expected to obtain a comparative analysis of the methods to determine the best processing, taking into account the cost / benefit of the whole process, as well as its reproducibility later, both by the Cord Blood Banks and the Blood Banks. (AU)